Pharmacokinetics of the angiotensin receptor-neprilysin inhibitor LCZ696 in furosemide-treated dogs

被引：0
|
作者：
Mochel, J. [1 ]
Seewald, W. [2 ]
Danhof, M. [3 ]
机构：
[1] Novartis Pharmaceut, Integrated Quantitat Sci, Basel, Switzerland
[2] Novartis, Elanco Anim Hlth, Dept Res & Dev, Basel, Switzerland
[3] Leiden Acad Ctr Drug Res, Dept Pharmacol, Leiden, Netherlands
来源：
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS | 2015年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
15.2
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [31] Effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril according to age in PARADIGM-HF
    Mcmurray, J. J. V.
    Jhund, P. S.
    Fu, M.
    Katova, T.
    Rouleau, J. L.
    Solomon, S. D.
    Swedberg, K.
    Zile, M.
    Salko, M.
    Packer, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 : 143 - 143
  • [32] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF LCZ696, A NOVEL DUAL-ACTING ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR (ARNI)
    Gu, J.
    Noe, A.
    Chandra, R.
    Al-Fayoumi, S.
    Ligueros, M.
    Sarangapani, R.
    Maahs, S.
    Ksander, G.
    Rigel, D.
    Jeng, A.
    Dole, W.
    JOURNAL OF HYPERTENSION, 2009, 27 : S9 - S9
  • [33] The angiotensin receptor and neprilysin inhibitor, LCZ696, in heart failure: A meta-analysis of randomized controlled trials
    Chen, Yan
    He, Qian
    Mo, Dun-Chang
    Chen, Long
    Lu, Jia-Lu
    Li, Rui-Xing
    Huang, Jie
    MEDICINE, 2022, 101 (41) : E30904
  • [34] Comparative efficacy of valsartan and LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI), in hypertensive individuals: effects of gender
    Ruilope, L. M.
    Izzo, J. L., Jr.
    Conde, L. G.
    Zappe, D. H.
    Zhang, Y.
    Zhang, J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 571 - 571
  • [35] LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates epithelial-mesenchymal transition of peritoneal mesothelial cells and M2 macrophage polarization
    Hu, Yan
    Zhou, Canxin
    Zhong, Qin
    Li, Xialin
    Li, Jinqing
    Shi, Yingfeng
    Ma, Xiaoyan
    Jiang, Daofang
    Wang, Yi
    Zhuang, Shougang
    Liu, Na
    RENAL FAILURE, 2024, 46 (02)
  • [36] Clinic blood pressure in stable heart failure patients treated with the dual-acting neprilysin and angiotensin receptor inhibitor LCZ696
    Kobalava, Z.
    Kotovskaya, Y.
    Meray, I.
    Globenko, A.
    Moiseev, V.
    Albrecht, D.
    Feng, A.
    Chandra, P.
    Jordaan, P.
    EUROPEAN HEART JOURNAL, 2011, 32 : 788 - 788
  • [37] LCZ696, the First-in-Class Angiotensin Receptor Neprilysin Inhibitor, Improves Vascular Reactivity in the Setting of Heart Failure
    Trivedi, Rishi K.
    Li, Zhen
    Polhemus, David J.
    Yoo, Daniel
    Koiwaya, Hiroshi
    Goodchild, Traci T.
    Lefer, David J.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 112 : 162 - 162
  • [38] Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial
    Lucchese B.
    Nature Reviews Nephrology, 2010, 6 (7) : 383 - 383
  • [39] Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects
    Akahori, Mizuki
    Ayalasomayajula, Surya
    Langenickel, Thomas
    Pal, Parasar
    Zhou, Wei
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (03) : 407 - 416
  • [40] Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects
    Mizuki Akahori
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Wei Zhou
    Gangadhar Sunkara
    European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42 : 407 - 416
12345